PRETREATMENT WITH FREQUENT TOPICAL BETAMETHASONE IN AHMED GLAUCOMA VALVE IMPLANTATION
Published 2022
- 26th ESCRS Winter Meeting
Reference: P273
| Type: Abstracts
| DOI:
10.82333/87ws-wh78
Authors:
Nader Nassiri* 1
, Maryam Yadgari 2
, Farsad Noorizadeh 2
, Kourosh Sheibani 2
, Sara Kavousnezhad 3
1Ophthalmology,Imam Hossein Medical Center, Shahid Beheshti University of Medical Sciences,Tehran,Iran, Islamic Republic Of, 2Ophthalmology,Basir Eye Health Research Center,Tehran,Iran, Islamic Republic Of, 3Ophthalmology,Vanak Eye Surgery Center,Tehran,Iran, Islamic Republic Of
Purpose
To evaluate the efficacy of pretreatment with topical betamethasone in Ahmed glaucoma valve (AGV) implantation.
Setting
Basir Eye Clinic, Tehran, Iran.
Methods
We randomly assigned patients undergoing AGV to 2 arms of the study. The case group received AGV implantation with preoperative betamethasone eye drops, and the control group did not receive preoperative betamethasone. Follow-up examinations were performed on postoperative day 1, at least weekly for 4 weeks, and then every 1 to 3 months. Our main outcome measure was the rate of success, defined as intraocular pressure (IOP) <15 mm Hg and IOP ≤18 mm Hg.
Results
We analyzed 62 eyes divided to case (n = 33) and control (n = 29) groups. The success rate was significantly higher in the intervention group than in the control group at 12 months postoperatively when considering either IOP < 15 or IOP < 18 mm Hg as success (p < 0.001) and also at 6 months when considering IOP < 18 mm Hg as success (p < 0.041). The reduction in the number of antiglaucoma medications used postoperatively was significantly higher in the betamethasone group at follow-up at 1 and 3 months and 1 year.
Conclusion
Pretreatment with topical betamethasone in AGV implantations increases the success rate and reduces the need for medications.